Myriad Genetics

Update in progress

MYGN (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDiagnostics & Research

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company that develops molecular tests for oncology, women’s health, pharmacogenomics, and prenatal screening. Its portfolio includes BRACAnalysis CDx, MyRisk, MyChoice CDx, Prolaris, EndoPredict, Precise Tumor Molecular Profile, Prequel Prenatal Screen, Foresight Carrier Screen, SneakPeek Early Gender, FirstGene, and GeneSight. It collaborates with Illumina and major medical centers. Founded 1991, based in Salt Lake City.

Company score

Sentiment: 0.28; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.29; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.04; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.18; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive